Ronald Blue & Co’s Myriad Genetics MYGN Stock Holding History

Ronald Blue & Co’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$208K	Buy	+8,062	New	+$171K	0.01%	207

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Ronald Blue & Co's MYGN Position: Q2 2017 in Review

Ronald Blue & Co opened a new position in Myriad Genetics (MYGN) in Q2 2017: 8,062 shares worth $208K. The stake represents 0.01% of the portfolio and ranks #207 among its holdings.

239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

Ronald Blue & Co held 8,062 shares of Myriad Genetics worth $208K as of Q2 2017.
Myriad Genetics was a new Ronald Blue & Co position in Q2 2017.
Myriad Genetics made up 0.01% of Ronald Blue & Co's portfolio in Q2 2017, its #207 holding.
239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Ronald Blue & Co's 13F filing for Q2 2017, filed 28 Jul 2017.